UA103221C2 - Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини - Google Patents

Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини

Info

Publication number
UA103221C2
UA103221C2 UAA201109963A UAA201109963A UA103221C2 UA 103221 C2 UA103221 C2 UA 103221C2 UA A201109963 A UAA201109963 A UA A201109963A UA A201109963 A UAA201109963 A UA A201109963A UA 103221 C2 UA103221 C2 UA 103221C2
Authority
UA
Ukraine
Prior art keywords
stimulating factor
colony stimulating
granulocyte colony
stable formulation
recombinant human
Prior art date
Application number
UAA201109963A
Other languages
English (en)
Russian (ru)
Inventor
Джейсон Бенджамін Бок
Ксіа Луо
Original Assignee
Тева Фармасьютікал Індастріз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютікал Індастріз Лтд. filed Critical Тева Фармасьютікал Індастріз Лтд.
Publication of UA103221C2 publication Critical patent/UA103221C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується фармацевтичної композиції, що містить рекомбінантний альбумін людини-гранулоцитарний колонієстимулюючий фактор людини і щонайменше один фармацевтично прийнятний носій, де композиція має рН від 4 до 6,4, а концентрація рекомбінантного гібридного білка становить від 30 до 120 мг/мл.
UAA201109963A 2009-01-16 2010-01-15 Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини UA103221C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544009P 2009-01-16 2009-01-16
US14543609P 2009-01-16 2009-01-16
PCT/US2010/021235 WO2010083434A2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
UA103221C2 true UA103221C2 (uk) 2013-09-25

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201109961A UA105201C2 (uk) 2009-01-16 2010-01-15 Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії
UAA201109963A UA103221C2 (uk) 2009-01-16 2010-01-15 Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201109961A UA105201C2 (uk) 2009-01-16 2010-01-15 Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії

Country Status (16)

Country Link
US (4) US8323634B2 (uk)
EP (2) EP2387419A2 (uk)
JP (2) JP5753095B2 (uk)
KR (2) KR20110132327A (uk)
CN (2) CN102378635A (uk)
AU (2) AU2010204547B2 (uk)
BR (2) BRPI1004940A2 (uk)
CA (2) CA2749802C (uk)
EA (2) EA023344B1 (uk)
IL (2) IL214051A0 (uk)
MX (2) MX2011007582A (uk)
NZ (2) NZ594055A (uk)
SG (3) SG172941A1 (uk)
UA (2) UA105201C2 (uk)
WO (2) WO2010083439A2 (uk)
ZA (1) ZA201105171B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110132327A (ko) 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
WO2011156373A1 (en) * 2010-06-07 2011-12-15 Amgen Inc. Drug delivery device
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
CA2896793A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
EP3328415B1 (en) * 2015-07-30 2020-11-25 Endor Technologies, S.L. Colony stimulating factor for use in pancreatic or colon cancer treatment
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
WO2018096534A1 (en) 2016-11-22 2018-05-31 Sorrel Medical Ltd. Apparatus for delivering a therapeutic substance
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
KR20200116477A (ko) * 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
EP3744368B1 (en) 2018-10-05 2026-02-18 LTS Device Technologies Ltd Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
JP2023505506A (ja) * 2019-12-05 2023-02-09 ハンミ ファーマシューティカルズ カンパニー リミテッド 化学療法または放射線療法で誘導された好中球減少症を治療する方法
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008027A1 (en) 1987-04-09 1988-10-20 Delta Biotechnology Limited Yeast vector
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
JP3895109B2 (ja) * 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
CA2449593A1 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20080108560A1 (en) * 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004082640A2 (en) * 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
MX2008001865A (es) * 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US8800782B2 (en) * 2006-04-13 2014-08-12 Wix Filtration Corp Llc Filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
KR20110132327A (ko) 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형

Also Published As

Publication number Publication date
EP2387420A2 (en) 2011-11-23
WO2010083439A2 (en) 2010-07-22
JP2012515222A (ja) 2012-07-05
SG196821A1 (en) 2014-02-13
AU2010204547A1 (en) 2011-07-28
AU2010204547B2 (en) 2014-01-23
CA2749786A1 (en) 2010-07-22
CN102395379B (zh) 2015-07-22
BRPI1004940A2 (pt) 2018-06-19
US20150202268A1 (en) 2015-07-23
IL214051A0 (en) 2011-08-31
JP5753095B2 (ja) 2015-07-22
KR20110132326A (ko) 2011-12-07
SG172940A1 (en) 2011-08-29
EA201190079A1 (ru) 2013-02-28
US8993519B2 (en) 2015-03-31
NZ594055A (en) 2013-03-28
MX2011007583A (es) 2011-12-14
IL214052A0 (en) 2011-08-31
EP2387419A2 (en) 2011-11-23
ZA201105171B (en) 2015-12-23
CA2749802C (en) 2016-08-23
KR20110132327A (ko) 2011-12-07
WO2010083434A2 (en) 2010-07-22
NZ594056A (en) 2013-03-28
US20100227818A1 (en) 2010-09-09
EA023344B1 (ru) 2016-05-31
AU2010204552B2 (en) 2014-05-01
CN102378635A (zh) 2012-03-14
US8323634B2 (en) 2012-12-04
SG172941A1 (en) 2011-08-29
MX2011007582A (es) 2011-12-14
JP2012515221A (ja) 2012-07-05
EA201190080A1 (ru) 2014-03-31
CA2749802A1 (en) 2010-07-22
BRPI1005159A2 (pt) 2018-04-03
UA105201C2 (uk) 2014-04-25
CN102395379A (zh) 2012-03-28
US20100297062A1 (en) 2010-11-25
WO2010083434A3 (en) 2010-09-10
WO2010083439A3 (en) 2010-09-10
US20130129669A1 (en) 2013-05-23
AU2010204552A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
UA103221C2 (uk) Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
MX377317B (es) Compuestos de hormona de crecimiento humana recombinante unidos a peg.
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
EA201190145A1 (ru) Фармацевтические композиции, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
MY161595A (en) Oral care compositions
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
PH12012501620A1 (en) Oral care compositions
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2013004062A (es) Analogos de ciclosporina.
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
BRPI0719885B8 (pt) peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição.
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
GB201101170D0 (en) Restorative materials
BR112015002726A8 (pt) combinação, composição farmacêutica, kit, e, usos de uma combinação, e de uma composição farmaceutica
WO2007015918A3 (en) Novel biologically active peptides and their new uses
EA201200753A1 (ru) Фармацевтическая композиция для лечения заболеваний мочевого пузыря
EA201200196A1 (ru) Составы для ухода за полостью рта, содержащие человеческий рекомбинантный интерлейкин-1
EA201291420A1 (ru) Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof